TARGET MET: BIOCON

BIOCON TARGET OF 378 MET...it touched 391.45 (+33% above my entry price of 295). Book 75% profits now (currently at 389). Hold rest for a target of 410.

On Mon, Sep 27, 2010 at 2:01 PM, POWERFULPICKS POWERFULPICKS <powerfulpicks@gmail.com> wrote:

BIOCON UPDATE: On Sep 26th, Biocon said that it has strengthened its existing research partnership with Cuba-based Center of Molecular Immunology (CMI) to create a product pipeline focused on autoimmune diseases and cancer. Financial terms of the partnership were not disclosed. Biocon has collaborated with CMI for almost 10 years to build a portfolio based on therapeutic biotechology products for chronic diseases, the company said.

On Thu, Sep 16, 2010 at 4:21 AM, powerfulpicks <powerfulpicks@gmail.com> wrote:

As you know that I cover Biocon and I had recommended Biocon at 295 for a target of 378 (see below call) to be achieved towards the end of October 2010.

 

Latest company news is that Biocon, has entered into an agreement with Teleradiology Solutions to offer its TRS Clinical Trials Radiology Reporting service to Clinigene, Biocon's Clinical Research Organization. The service is provided by its team of radiologists experienced in RECIST (Response Evaluation Criteria In Solid Tumours) which adhere to the World Health Organisation measurement criteria.

By using TRS Clinical Trials Radiology Reporting service, pharmaceutical vendors, clinical research organizations and biotechnology companies can shorten their development cycle time. Teleradiology's quality-driven reporting process and technology platform has the potential to benefit biotech and pharma companies, obviating delays in the completion of clinical trials by optimizing the radiology reporting process. Clinical trials radiology is a unique service and the objective is to demonstrate the efficacy, safety and cost utility of a new therapy for regulatory approval, with the fewest patients and in the shortest time possible.

According to Kiran Mazumdar-Shaw, chairman & managing director of Biocon Ltd, to achieve our main objective of accelerating clinical research, we leverage on an adept mix of technology, experience and personal traits. Keeping in line with our mission, Teleradiology Solutions, given their impressive track record, was the partner of choice to meet our complex image analysis requirements. "The signing of this agreement further endorses Bangalore as the hub of excellence, both in Biotechnology as well as in high end healthcare delivery to the world," she added.

"For pharmaceutical and biotechnology companies involved in drug development R&D, delays in the drug development cycle can be an issue of concern. These are in part related to delays in reporting of radiologic scans that are performed to confirm that the patient under treatment has responded positively to the drug being evaluated in the clinical trial. The delays are in turn related to the worldwide shortage of radiologists, estimated to be as high as 20 per cent in some studies. We are happy to partner with Biocon and offer our services to ensure timely execution and quality evaluation for clinical trials in radiology," stated Dr Arjun Kalyanpur, MD and chief radiologists, Teleradiology Solutions.

 

Sent: Saturday, July 24, 2010 9:00 PM
To: 'powerfulpicks@yahoogroups.co.in'
Subject: I am revising my target price for Biocon
Importance: High

 

As you know that I cover Biocon and I had recommended Biocon at 295 for a target of 365 to be achieved towards the end of October 2010. On July 23^rd, it touched 335.70.

 

Biocon has had exceptionally good results in Q1 and Q2 holds greater promise. Biocon is shifting focus on emerging markets like Africa, Latin America and the middle east which gives around 20% growth on an average compared to regulated markets of developed countries, which gives growth of around 6-8%. 3 more verticals being added to their branded formulations segment – eye care, dermatology, immune-therapy & comprehensive care.

 

I am revising Biocon's end-October 2010 target to 378, with an upward bias (meaning that it may attain a price that is slightly higher than the target price) to account for the significant growth plans.

 

From: powerfulpicks@yahoogroups.co.in
Sent: Monday, April 26, 2010 8:51 AM To: powerfulpicks@yahoogroups.co.in
Subject: [powerfulpicks] BUY: BIOCON at 293-295

 

 BUY: BIOCON at 293-295 for a 6 month target of 365 (around 24% upside)